Merck receives CHMP positive opinion recommending approval of ISENTRESS® (raltegravir)
Merck announced the Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion recommending approval of ISENTRESS® (raltegravir) 600 mg film-coated tablets, in combination with other anti-retroviral medicinal products, for treatment of HIV-1 infection. May 19, 2017
